vs
Orthofix Medical Inc.（OFIX）与WSFS FINANCIAL CORP（WSFS）财务数据对比。点击上方公司名可切换其他公司
WSFS FINANCIAL CORP的季度营收约是Orthofix Medical Inc.的1.3倍（$275.3M vs $219.9M），WSFS FINANCIAL CORP净利率更高（31.5% vs -1.0%，领先32.5%），WSFS FINANCIAL CORP同比增速更快（7.5% vs 2.0%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 1.7%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
WSFS金融集团是一家金融服务企业，核心子公司WSFS银行是总部位于特拉华州及大特拉华谷地区规模最大、经营历史最久的本地管理银行与财富管理机构。集团共运营115个网点，其中88个为银行网点，分布在宾夕法尼亚、特拉华、新泽西、佛罗里达、弗吉尼亚、内华达六州，提供全面金融服务。
OFIX vs WSFS — 直观对比
营收规模更大
WSFS
是对方的1.3倍
$219.9M
营收增速更快
WSFS
高出5.5%
2.0%
净利率更高
WSFS
高出32.5%
-1.0%
两年增速更快
OFIX
近两年复合增速
1.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $275.3M |
| 净利润 | $-2.2M | $86.8M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | — |
| 净利率 | -1.0% | 31.5% |
| 营收同比 | 2.0% | 7.5% |
| 净利润同比 | 92.4% | 31.7% |
| 每股收益（稀释后） | $-0.05 | $1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXWSFS
| Q1 26 | — | $275.3M | ||
| Q4 25 | $219.9M | $271.9M | ||
| Q3 25 | $205.6M | $270.5M | ||
| Q2 25 | $203.1M | $267.5M | ||
| Q1 25 | $193.6M | $256.1M | ||
| Q4 24 | $215.7M | $261.5M | ||
| Q3 24 | $196.6M | $267.7M | ||
| Q2 24 | $198.6M | $266.0M |
净利润OFIXWSFS
| Q1 26 | — | $86.8M | ||
| Q4 25 | $-2.2M | $72.7M | ||
| Q3 25 | $-22.8M | $76.4M | ||
| Q2 25 | $-14.1M | $72.3M | ||
| Q1 25 | $-53.1M | $65.9M | ||
| Q4 24 | $-29.1M | $64.2M | ||
| Q3 24 | $-27.4M | $64.4M | ||
| Q2 24 | $-33.4M | $69.3M |
毛利率OFIXWSFS
| Q1 26 | — | — | ||
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — |
营业利润率OFIXWSFS
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 35.8% | ||
| Q3 25 | -8.3% | 37.3% | ||
| Q2 25 | -7.9% | 35.7% | ||
| Q1 25 | -25.2% | 34.0% | ||
| Q4 24 | -5.3% | 32.3% | ||
| Q3 24 | -9.6% | 31.9% | ||
| Q2 24 | -12.5% | 34.0% |
净利率OFIXWSFS
| Q1 26 | — | 31.5% | ||
| Q4 25 | -1.0% | 26.7% | ||
| Q3 25 | -11.1% | 28.3% | ||
| Q2 25 | -6.9% | 27.0% | ||
| Q1 25 | -27.4% | 25.7% | ||
| Q4 24 | -13.5% | 24.6% | ||
| Q3 24 | -13.9% | 24.1% | ||
| Q2 24 | -16.8% | 26.0% |
每股收益（稀释后）OFIXWSFS
| Q1 26 | — | $1.64 | ||
| Q4 25 | $-0.05 | $1.33 | ||
| Q3 25 | $-0.57 | $1.37 | ||
| Q2 25 | $-0.36 | $1.27 | ||
| Q1 25 | $-1.35 | $1.12 | ||
| Q4 24 | $-0.76 | $1.08 | ||
| Q3 24 | $-0.71 | $1.08 | ||
| Q2 24 | $-0.88 | $1.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $2.7B |
| 总资产 | $850.6M | $22.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXWSFS
| Q1 26 | — | — | ||
| Q4 25 | $82.0M | $1.7B | ||
| Q3 25 | $62.9M | — | ||
| Q2 25 | $65.6M | — | ||
| Q1 25 | $58.0M | — | ||
| Q4 24 | $83.2M | $1.2B | ||
| Q3 24 | $30.1M | — | ||
| Q2 24 | $26.4M | — |
总债务OFIXWSFS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — |
股东权益OFIXWSFS
| Q1 26 | — | $2.7B | ||
| Q4 25 | $450.0M | $2.7B | ||
| Q3 25 | $442.5M | $2.8B | ||
| Q2 25 | $458.3M | $2.7B | ||
| Q1 25 | $458.3M | $2.7B | ||
| Q4 24 | $503.1M | $2.6B | ||
| Q3 24 | $525.9M | $2.7B | ||
| Q2 24 | $546.0M | $2.5B |
总资产OFIXWSFS
| Q1 26 | — | $22.1B | ||
| Q4 25 | $850.6M | $21.3B | ||
| Q3 25 | $832.6M | $20.8B | ||
| Q2 25 | $837.2M | $20.8B | ||
| Q1 25 | $823.1M | $20.5B | ||
| Q4 24 | $893.3M | $20.8B | ||
| Q3 24 | $867.9M | $20.9B | ||
| Q2 24 | $882.0M | $20.7B |
负债/权益比OFIXWSFS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | — |
| 自由现金流经营现金流 - 资本支出 | $16.8M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXWSFS
| Q1 26 | — | — | ||
| Q4 25 | $27.7M | $220.0M | ||
| Q3 25 | $12.4M | $121.5M | ||
| Q2 25 | $11.6M | $37.2M | ||
| Q1 25 | $-18.4M | $8.7M | ||
| Q4 24 | $23.7M | $219.9M | ||
| Q3 24 | $11.7M | $3.1M | ||
| Q2 24 | $9.0M | $44.8M |
自由现金流OFIXWSFS
| Q1 26 | — | — | ||
| Q4 25 | $16.8M | $213.6M | ||
| Q3 25 | $2.5M | $120.3M | ||
| Q2 25 | $4.5M | $35.2M | ||
| Q1 25 | $-25.1M | $6.3M | ||
| Q4 24 | $15.2M | $205.6M | ||
| Q3 24 | $6.3M | $-489.0K | ||
| Q2 24 | $-360.0K | $42.1M |
自由现金流率OFIXWSFS
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 78.6% | ||
| Q3 25 | 1.2% | 44.5% | ||
| Q2 25 | 2.2% | 13.2% | ||
| Q1 25 | -13.0% | 2.5% | ||
| Q4 24 | 7.0% | 78.6% | ||
| Q3 24 | 3.2% | -0.2% | ||
| Q2 24 | -0.2% | 15.8% |
资本支出强度OFIXWSFS
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 2.3% | ||
| Q3 25 | 4.8% | 0.5% | ||
| Q2 25 | 3.5% | 0.7% | ||
| Q1 25 | 3.5% | 0.9% | ||
| Q4 24 | 4.0% | 5.5% | ||
| Q3 24 | 2.7% | 1.4% | ||
| Q2 24 | 4.7% | 1.0% |
现金转化率OFIXWSFS
| Q1 26 | — | — | ||
| Q4 25 | — | 3.03× | ||
| Q3 25 | — | 1.59× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 0.13× | ||
| Q4 24 | — | 3.43× | ||
| Q3 24 | — | 0.05× | ||
| Q2 24 | — | 0.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
WSFS
暂无分部数据
